Why the study?
Colchicine shows promise in reducing cardiovascular risk, but a recent study questioned whether this is really the case.
Does low-dose colchicine reduce major adverse cardiovascular events in patients requiring secondary prevention?
Population
21,774 patients across six RCTs in secondary prevention
Comparison
Colchicine vs placebo
Design
Meta-analysis of RCTs
Key result
Low-dose colchicine significantly reduced the risk of major adverse cardiovascular events compared to placebo in secondary prevention (RR 0.74; 95% CI 0.60-0.92).
Authors
Loading...
Colchicine reduces MACE in secondary prevention; reinforces its role and supports updated guidelines.
Meta-Analysis (n=21,774)
Does low-dose colchicine reduce major adverse cardiovascular events in patients requiring secondary prevention?
Relative Risk: 0.74 (95% CI 0.6–0.92)
Low-dose colchicine added to standard care for at least 12 months significantly reduces the risk of MACE, myocardial infarction, and stroke in secondary prevention.
Xie et al. (2025) conducted a meta-analysis in Cardiovascular risk in secondary prevention (n=21,774). Colchicine vs. Placebo was evaluated on Major adverse cardiovascular events (MACEs) (RR 0.74, 95% CI 0.60-0.92). Low-dose colchicine significantly reduced the risk of major adverse cardiovascular events compared to placebo in secondary prevention (RR 0.74; 95% CI 0.60-0.92).